Medwave Inc., of Danvers, Mass., has received clearance to market Fusion, the first completely sensor-based monitor to evaluate BP and vital signs. Studies have demonstrated that the accuracy of Medwave’s core sensor-based BP technology is comparable to that of an invasive arterial catheter. The new monitor, which takes readings at the wrist, expands the technology by incorporating sensor-based pulse oximetry by Nellcor and thermometry by Kendall (both operating companies of Tyco Healthcare Group, LP, of Mansfield, Mass.). “Health providers now have a device to continually monitor vital signs without invasive techniques. That’s something we never could have imagined 30 years ago,” said Medwave chief executive officer Tim O’Malley.
Please login or register first to view this content.